U.S. Department of Health and Human Services
NATIONAL INSTITUTES OF HEALTH NIH News
National Institute of Allergy and Infectious Diseases (NIAID)
For Immediate Release: Tuesday, November 30, 2021
Media Contact: NIAID News & Science Writing Branch, (301) 402-1663, <e-mail:niaidnews@xxxxxxxxxxxxx>
MEDIA AVAILABILITY
TOO MANY PEOPLE WITH HIV FAIL TO ACHIEVE DURABLE VIRAL SUPPRESSION
NIH-funded study estimates global progress toward UNAIDS goal
WHAT:
Among people with HIV worldwide who are receiving antiretroviral therapy (ART), adults are getting closer to the global target of 95% achieving viral suppression, but progress among children and adolescents is lagging and long-term viral suppression among all groups remains a challenge. These findings of a study funded by the National Institutes of Health suggest that substantial efforts are needed to help people with HIV durably suppress the virus. The findings were published today in the journal The Lancet HIV.
People with HIV who achieve viral suppression protect their immune health and prevent transmitting HIV to others. In 2014, the Joint United Nations Programme on HIV/AIDS (UNAIDS) set a goal <https://www.unaids.org/sites/default/files/media_asset/201506_JC2743_Understanding_FastTrack_en.pdf>of 95% of all people with HIV who are taking ART achieving viral suppression by 2030.
Scientists from the National Institutes of Health-funded International epidemiology Databases to Evaluate AIDS (IeDEA) <https://www.iedea.org/> consortium set out in 2020 to estimate how close the world is to achieving that goal. The study was led by Win Min Han, M.B.B.S., M.Sc., a Ph.D. student-researcher at the Kirby Institute of the University of New South Wales in Sydney, Australia; Azar Kariminia, Ph.D., a senior lecturer at the Kirby Institute; and Matthew G. Law, Ph.D., head of the Biostatistics and Databases Program and professor of biostatistics at the Kirby Institute. Funding for IeDEA comes from the National Institute of Allergy and Infectious Diseases (NIAID), part of NIH, and from eight other NIH institutes and centers.
The investigators analyzed data from 148 IeDEA treatment sites in 31 countries on five continents to estimate the proportions of children, adolescents and adults who were virally suppressed one, two and three years after initiating ART. The data came from more than 21,500 children and adolescents with HIV aged 17 years or younger and more than 255,000 adults with HIV, all of whom had begun receiving ART between 2010 and 2019. Viral suppression was defined as having fewer than 1,000 copies of HIV per milliliter of blood.
The researchers calculated the percentages of children and adults who were virally suppressed based on data from those who were alive, in follow-up, and had viral load measurements for up to three years of ART. To further estimate viral suppression among people who had fallen out of HIV care during a three-year interval, the investigators looked to a Zambian study of viral suppression rates in a similar population and calculated an adjustment to viral suppression rates in the IeDEA population.
The researchers estimated that among adults, 79% were virally suppressed after one year of ART, 72% after two years and 65% after three years. Among children and adolescents, 64% were virally suppressed after one year of ART, 62% after two years and 59% after three years. These viral suppression rates illustrate how much farther global HIV treatment programs need to go to reach and sustain the UNAIDS 2030 targets, according to the investigators. Importantly, the even lower rates of viral suppression among children and adolescents with HIV underscore the need to improve approaches for achieving durable viral suppression in these age groups.
ARTICLE:
WM Han et al. Global estimates of viral suppression in children and adolescents and adults on antiretroviral therapy adjusted for missing viral load measurements: a multiregional, retrospective cohort study in 31 countries <https://www.thelancet.com/journals/lanhiv/article/PIIS2352-3018(21)00265-4/fulltext>. The Lancet HIV (2021).
WHO:
Carl Dieffenbach, Ph.D., director of the NIAID Division of AIDS, is available to comment on this study.
NIAID conducts and supports research-at NIH, throughout the United States, and worldwide-to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID website <https://www.niaid.nih.gov/>.
About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit <www.nih.gov>.
NIH...Turning Discovery into Health -- Registered, U.S. Patent and Trademark Office
###
This NIH News Release is available online at:
<https://www.nih.gov/news-events/news-releases/too-many-people-hiv-fail-achieve-durable-viral-suppression>
To subscribe (or unsubscribe) from NIH News Release mailings, go to
<http://service.govdelivery.com/service/subscribe.html?code=USNIH_1>.
If you subscribed via the NIH LISTSERV, go to <https://list.nih.gov/cgi-bin/wa.exe?A0=nihpress>.
